THIOCTIC ACID
本记录确认了用于欧盟化妆品标签标示的官方通用成分名称。它本身并不能确认该物质获准使用、不受限制或安全。
全球证据概览
所解析的身份在 13 个已索引市场数据集中的 1 个有匹配的监管证据:1 条国家记录和 0 条欧盟附件记录。下方列出每项结果和证据缺口。
已解析的物质身份
3 个匹配或报告的名称
全部 13 个市场的监管证据
打开每条匹配记录,查看其范围、浓度、条件、警示语和官方来源版本。
滑动或横向滚动以查看数据集覆盖范围和后续操作。
| 市场 | 结果 | 记录 | 数据集 | 含义 / 后续操作 |
|---|---|---|---|---|
| European Union EU | 未找到匹配项 | 0 | Complete annex dataset Regulation (EC) 1223/2009 consolidated to 1 May 2026 | No annex match only means that these five annexes did not return a match; CosIng identity data and other EU obligations still need review. |
| Great Britain GB | 未找到匹配项 | 0 | Complete consolidated annex dataset GB retained Regulation 1223/2009 schedules, effective 15 August 2026 | No annex match is not approval and does not cover Northern Ireland, which follows the applicable EU framework. |
| Canada CA | 未找到匹配项 | 0 | Complete Hotlist snapshot Health Canada Cosmetic Ingredient Hotlist, 13 August 2025 | The Hotlist is an administrative compliance tool, not an exhaustive safety approval list. |
| New Zealand NZ | 未找到匹配项 | 0 | Complete schedules dataset Cosmetic Products Group Standard schedules effective 1 January 2026 | The searchable spreadsheet is an aid; the legal Group Standard and incorporated notices remain authoritative. |
| ASEAN ASEAN | 未找到匹配项 | 0 | Complete regional annex dataset ASEAN Cosmetic Directive annexes 2026-1, 22 June 2026 | Regional annex coverage does not replace member-state implementation dates, notifications or national deviations. |
| China CN | 未找到匹配项 | 0 | Complete prohibited catalogues plus official-source workflow NMPA 2021 banned catalogues plus dynamic IECIC List I/List II system current since 2025 | IECIC listing is not blanket approval; absence may require the new cosmetic ingredient route, and restrictions are checked separately. |
| Japan JP | Restricted | 1打开记录 1 | Complete Standards appendices dataset MHLW Standards for Cosmetics official English source and Japanese amendments checked for the imported snapshot | 请查看每条关联记录及其确切条件。 |
| South Korea KR | 未找到匹配项 | 0 | Complete current appendix dataset MFDS Notice 2026-19, effective 18 March 2026 | Korean source wording is canonical and other positive lists/notices may still apply to the formulation. |
| United States US | 未找到匹配项 | 0 | Complete enumerated federal ingredient rules eCFR Title 21 issue date 27 August 2026 | FDA has no general approved-cosmetic-ingredient catalogue; absence from these sections is not approval or proof of safety. |
| Australia AU | 未找到匹配项 | 0 | Complete cosmetic-relevant Poisons Standard subset plus official workflow Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026 | An AICIS Inventory match is not cosmetic approval; no Inventory match can indicate a new, exempted, reported or confidential introduction. |
| Brazil BR | 未找到匹配项 | 0 | Complete prohibited dataset plus current restricted-list workflow ANVISA RDC 1.029/2026 and RDC 1.030/2026, published 15 June 2026 | RDC 1.030/2026 amends rather than replaces the prohibited baseline, and the second restricted-list revision was still under consultation in July 2026. |
| India IN | 未找到匹配项 | 0 | Complete current Part 2 dataset plus official workflow for Parts 1, 3 and 4 Cosmetics Rules 2020 plus current BIS IS 4707 parts (1:2020, 2:2025, 3:2025, 4:2022) | The standards are separate controlled publications; absence from a locally indexed excerpt is not permission. |
| Saudi Arabia SA | 未找到匹配项 | 0 | Complete official list index SFDA live prohibited/restricted lists, snapshot 30 August 2026 | No list match is not permission; Gulf/SFDA product, claim, notification and technical requirements still apply. |
匹配的市场记录和条件
化学身份与性质

alpha Lipoic acid
Lipoic acid is a heterocyclic thia fatty acid comprising pentanoic acid with a 1,2-dithiolan-3-yl group at the 5-position. It has a role as a geroprotector and a fundamental metabolite. It is a member of dithiolanes, a heterocyclic fatty acid and a thia fatty acid. It is functionally related to an octanoic acid. It is a conjugate acid of a lipoate. — ChEBI
- IUPAC 名称
- 5-(dithiolan-3-yl)pentanoic acid
- 分子式
- C8H14O2S2
- 分子量
- 206.3 g/mol
- 精确质量
- 206.04352203 Da
- XLogP3
- 1.7
- 拓扑极性表面积
- 87.9 Ų
- 氢键供体
- 1
- 氢键受体
- 4
- 共价单元
- 1
- 已定义的立体中心
- 0
又称
另有 16 个已报告名称
外部数据库标识符
- ChEBI:CHEBI:16494
- ChEMBL:CHEMBL33864
- EPA DTXSID:DTXSID7025508
- PubMed:22654724
- PubMed:22448096
- PubMed:22384101
- PubMed:22374556
- PubMed:22363901
- PubMed:22272085
- PubMed:22242957
- PubMed:22163871
- PubMed:22163517
- PubMed:22146387
- PubMed:22125679
- PubMed:22125537
来自其他科学数据库的证据
NIH PubChem PUG-View
Attributed physical-property, hazard, environmental and use annotations.
- Color/Form: Forms yellowish flakes 来源: Hazardous Substances Data Bank (HSDB)
- Dissociation Constants: pKa = 5.10 来源: Hazardous Substances Data Bank (HSDB)
- Melting Point: 47.5-48 °C 来源: Hazardous Substances Data Bank (HSDB)
- Solubility: Yellow powder; solubility in ethanol: 50 mg/mL /Synthetic, oxidized form/ 来源: Hazardous Substances Data Bank (HSDB)
- Solubility: Soluble in methanol, ethanol, diethyl ether and chloroform 来源: Hazardous Substances Data Bank (HSDB)
- Carcinogen Classification: No indication of carcinogenicity to humans (not listed by IARC). 来源: Toxin and Toxin Target Database (T3DB)
- Note: This chemical does not meet GHS hazard criteria for 6.5% (28 of 430) of reports. 来源: European Chemicals Agency (ECHA)
- Signal: Warning 来源: European Chemicals Agency (ECHA)
- GHS Hazard Statements: H302 (93.5%): Harmful if swallowed [Warning Acute toxicity, oral]; H315 (48.6%): Causes skin irritation [Warning Skin corrosion/irritation]; H317 (46.5%): May cause an allergic skin reaction [Warning Sensitization, Skin]; H319 (47%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]; H411 (46.5%): Toxic to aquatic life with long lasting effects [Hazardous to the aquatic environment, long-term hazard] 来源: European Chemicals Agency (ECHA)
- Precautionary Statement Codes: P261, P264, P264+P265, P270, P272, P273, P280, P301+P317, P302+P352, P305+P351+P338, P321, P330, P332+P317, P333+P317, P337+P317, P362+P364, P391, and P501 (click each P-code to see the statement) 来源: European Chemicals Agency (ECHA)
- ECHA C&L Notifications Summary: Aggregated GHS information provided per 430 reports by companies from 16 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.; Reported as not meeting GHS hazard criteria per 28 of 430 reports by companies.; There are 14 notifications provided by 402 of 430 reports by companies with hazard statement code(s).; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. 来源: European Chemicals Agency (ECHA)
- Note: This chemical does not meet GHS hazard criteria for 42.3% (52 of 123) of reports. 来源: European Chemicals Agency (ECHA)
- GHS Hazard Statements: H302 (57.7%): Harmful if swallowed [Warning Acute toxicity, oral]; H315 (31.7%): Causes skin irritation [Warning Skin corrosion/irritation]; H319 (31.7%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]; H335 (31.7%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation]; H412 (19.5%): Harmful to aquatic life with long lasting effects [Hazardous to the aquatic environment, long-term hazard] 来源: European Chemicals Agency (ECHA)
- Precautionary Statement Codes: P261, P264, P264+P265, P270, P271, P273, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement) 来源: European Chemicals Agency (ECHA)
- ECHA C&L Notifications Summary: Aggregated GHS information provided per 123 reports by companies from 8 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.; Reported as not meeting GHS hazard criteria per 52 of 123 reports by companies.; There are 7 notifications provided by 71 of 123 reports by companies with hazard statement code(s).; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. 来源: European Chemicals Agency (ECHA)
- Health Effects: Acute exposure to cholinesterase inhibitors can cause a cholinergic crisis characterized by severe nausea/vomiting, salivation, sweating, bradycardia, hypotension, collapse, and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved. Accumulation of ACh at motor nerves causes overstimulation of nicotinic expression at the neuromuscular junction. When this occurs symptoms such as muscle weakness, fatigue, muscle cramps, fasciculation, and paralysis can be seen. When there is an accumulation of ACh at autonomic ganglia this causes overstimulation of nicotinic expression in the sympathetic system. Symptoms associated with this are hypertension, and hypoglycemia. Overstimulation of nicotinic acetylcholine receptors in the central nervous system, due to accumulation of ACh, results in anxiety, headache, convulsions, ataxia, depression of respiration and circulation, tremor, general weakness, and potentially coma. When there is expression of muscarinic overstimulation due to excess acetylcholine at muscarinic acetylcholine receptors symptoms of visual disturbances, tightness in chest, wheezing due to bronchoconstriction, incre 来源: Toxin and Toxin Target Database (T3DB)
- Toxicity Summary: ALA is generally considered a safe drug. A daily dose of 200 mg/day to 2400 mg/day of ALA is deemed safe without significant adverse effects. However, there is no reported safe dose in children.; A notable case in literature demonstrated status epilepticus (SE) that subsided within a few days. The seizures were treated per normal standards for SE.; In the last 2 decades, there have been few reported cases of ALA toxicity in humans. Most of these cases occur in children and are treatable. Though there is no established lethal dosage of ALA for humans, studies have shown that a high dose of 121 mg/kg body weight/day was associated with alterations in liver enzymes and liver function. Therefore, there are potentially harmful adverse effects from overdosing on ALA, and more studies are necessary to determine the toxicity. 来源: StatPearls
- Toxicity Summary: (R)-lipoic acid is a cholinesterase or acetylcholinesterase (AChE) inhibitor. A cholinesterase inhibitor (or 'anticholinesterase') suppresses the action of acetylcholinesterase. Because of its essential function, chemicals that interfere with the action of acetylcholinesterase are potent neurotoxins, causing excessive salivation and eye-watering in low doses, followed by muscle spasms and ultimately death. Nerve gases and many substances used in insecticides have been shown to act by binding a serine in the active site of acetylcholine esterase, inhibiting the enzyme completely. Acetylcholine esterase breaks down the neurotransmitter acetylcholine, which is released at nerve and muscle junctions, in order to allow the muscle or organ to relax. The result of acetylcholine esterase inhibition is that acetylcholine builds up and continues to act so that any nerve impulses are continually transmitted and muscle contractions do not stop. Among the most common acetylcholinesterase inhibitors are phosphorus-based compounds, which are designed to bind to the active site of the enzyme. The structural requirements are a phosphorus atom bearing two lipophilic groups, a leaving group (such as 来源: Toxin and Toxin Target Database (T3DB)
- Uses: Nutrition, biochemical research /Thioctic acid, dl-form/ 来源: Hazardous Substances Data Bank (HSDB)
- Uses: THERAPEUTIC CATEGORY: Treatment of liver disease; antidote to poisonous mushrooms (Amanita species). 来源: Hazardous Substances Data Bank (HSDB)
- Uses: Use (kg; approx.) in Germany (2009): >7500; Consumption (g per capita; approx.) in Germany (2009): 0.0916; Calculated removal (%): 96.4 来源: NORMAN Suspect List Exchange
- Uses: For nutritional supplementation, also for treating dietary shortage or imbalance. 来源: Toxin and Toxin Target Database (T3DB)
映射方: Existing checksum-valid CAS to unique PubChem CID match. 检索时间: 2026-08-31. 打开来源记录
科学分类和危害注释仅提供背景信息,不能取代上方所示针对具体市场的监管决定。
其他来源的覆盖范围和匹配状态
| 来源 | 结果 | 已检查 |
|---|---|---|
| NIH PubChem PUG-View | 精确匹配 | 2026-08-31 |
已记录的无匹配结果是该来源已被检查的有效证据;这并不表示该物质在别处不存在。
于 2026-09-02 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。
官方来源与范围
导入自委员会实施决定 (EU) 2025/1175(数据集版本 EU 2025/1175)。词汇表为第 19(1)(g) 条所要求的成分表提供通用成分名称;它不是准许清单或安全清单。
打开官方决定